• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Is CLDN12 a novel biomarker or a novel target for cervical cancer and endometrial cancer?

Research Project

Project/Area Number 20K18224
Research Category

Grant-in-Aid for Early-Career Scientists

Allocation TypeMulti-year Fund
Review Section Basic Section 56040:Obstetrics and gynecology-related
Research InstitutionFukushima Medical University

Principal Investigator

Endo Yuta  福島県立医科大学, 医学部, 助教 (00868896)

Project Period (FY) 2020-04-01 – 2023-03-31
Project Status Completed (Fiscal Year 2022)
Budget Amount *help
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2022: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2021: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Keywords子宮頸癌 / 子宮体癌 / 細胞接着 / クローディン / がん診断マーカー / 細胞間接着 / がん / バイオマーカー / CLDN12
Outline of Research at the Start

細胞間接着分子クローディン(CLDNs)の発現パターンは、腫瘍の診断マーカー及び予後マーカーとして有用である。申請者はThe Cancer Genome Atlasデータベースで、細胞間接着分子クローディン-12(CLDN12)mRNAの高発現が子宮頸癌と子宮体癌の予後不良因子である可能性が指摘されていることに着目した。
本研究では、子宮頸癌と子宮体癌の手術検体を用いてCLDN12発現の臨床病理学的意義を明らかにし、これらの培養細胞株を用いてCLDN12による腫瘍細胞制御機構を解明して、新規診断マーカー及び新規治療標的としての有用性を検証する。

Outline of Final Research Achievements

Within the claudin (CLDN) family, CLDN12 mRNA expression is altered in various types of cancer, but its clinicopathological relevance has yet to be established due to the absence of specific antibodies (Abs) with broad applications. We generated a monoclonal Ab (mAb) against human/mouse CLDN12 and verified its specificity. By performing immunohistochemical staining and semiquantification, we evaluated the relationship between CLDN12 expression and clinicopathological parameters in cervical cancer tissues. The disease-specific survival (DSS) and recurrence-free survival rates were significantly decreased compared with those in the high CLDN12 expression group. We also demonstrated, via univariable and multivariable analyses, that the low CLDN12 expression represents a significant prognostic factor for the DSS of cervical cancer patients. It can be concluded that a reduced CLDN12 expression predicts a poor outcome for cervical cancer.

Academic Significance and Societal Importance of the Research Achievements

クローディン12低発現が子宮頸癌の予後不良因子であることを明らかにした。新規の抗クローディン12モノクローナル抗体は、多様ながん種や他の疾患におけるクローディン12発現の生物学的関連性を評価するために有用であると考えられる。近年、他のクローディンファミリーのがん診断マーカーとしての有用性も示されており、抗体カクテルや抗体パネルによる層別化や新規の治療標的への応用が期待される。

Report

(4 results)
  • 2022 Annual Research Report   Final Research Report ( PDF )
  • 2021 Research-status Report
  • 2020 Research-status Report
  • Research Products

    (7 results)

All 2022 2021 2020

All Journal Article (4 results) (of which Int'l Joint Research: 3 results,  Peer Reviewed: 4 results,  Open Access: 4 results) Presentation (3 results)

  • [Journal Article] Claudin-9 is a novel prognostic biomarker for endometrial cancer2022

    • Author(s)
      Endo Yuta、Sugimoto Kotaro、Kobayashi Makoto、Kobayashi Yasuyuki、Kojima Manabu、Furukawa Shigenori、Soeda Shu、Watanabe Takafumi、Higashi Atsuko、Higashi Tomohito、Hashimoto Yuko、Fujimori Keiya、Chiba Hideki
    • Journal Title

      International Journal of Oncology

      Volume: 61 Issue: 5 Pages: 135-135

    • DOI

      10.3892/ijo.2022.5425

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Reduced Claudin-12 Expression Predicts Poor Prognosis in Cervical Cancer2021

    • Author(s)
      Rahman Abidur、Kobayashi Makoto、Sugimoto Kotaro、Endo Yuta、Kojima Manabu、Furukawa Shigenori、Watanabe Takafumi、Soeda Shu、Hashimoto Yuko、Fujimori Keiya、Chiba Hideki
    • Journal Title

      International Journal of Molecular Sciences

      Volume: 22 Issue: 7 Pages: 3774-3774

    • DOI

      10.3390/ijms22073774

    • Related Report
      2021 Research-status Report 2020 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Aberrant Claudin-6?Adhesion Signaling Promotes Endometrial Cancer Progression via Estrogen Receptor α2021

    • Author(s)
      Kojima Manabu、Sugimoto Kotaro、Kobayashi Makoto、Ichikawa-Tomikawa Naoki、Kashiwagi Korehito、Watanabe Takafumi、Soeda Shu、Fujimori Keiya、Chiba Hideki
    • Journal Title

      Molecular Cancer Research

      Volume: 19 Issue: 7 Pages: 1208-1220

    • DOI

      10.1158/1541-7786.mcr-20-0835

    • Related Report
      2021 Research-status Report 2020 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Prognostic Significance of Aberrant Claudin-6 Expression in Endometrial Cancer2020

    • Author(s)
      Kojima Manabu、Sugimoto Kotaro、Tanaka Mizuko、Endo Yuta、Kato Hitomi、Honda Tsuyoshi、Furukawa Shigenori、Nishiyama Hiroshi、Watanabe Takafumi、Soeda Shu、Fujimori Keiya、Chiba Hideki
    • Journal Title

      Cancers

      Volume: 12 Issue: 10 Pages: 2748-2748

    • DOI

      10.3390/cancers12102748

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Presentation] Claudin-9 is a novel biomarker of the prognosis of Endometrial cancer2022

    • Author(s)
      Yuta Endo, Shu Soeda, Tetsu Sato, Chikako Okabe, Makiko Ueda, Norihito Kamo, Manabu Kojima, Shigeori Furukawa, Takafumi Watanabe, Keiya Fujimori
    • Organizer
      第74回日本産科婦人科学会学術講演会
    • Related Report
      2022 Annual Research Report
  • [Presentation] Claudin-9は子宮内膜癌の予後不良因子である2021

    • Author(s)
      遠藤雄大、杉本幸太郎、小林信、藤森敬也、千葉英樹
    • Organizer
      第111回日本病理学会総会
    • Related Report
      2021 Research-status Report
  • [Presentation] Claudin-9は子宮体がんの新規予後マーカーである2021

    • Author(s)
      遠藤 雄大,杉本 幸太郎,Abidur Rahman,小林 信,千葉 英樹
    • Organizer
      第72回日本電気泳動学会総会
    • Related Report
      2021 Research-status Report

URL: 

Published: 2020-04-28   Modified: 2024-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi